癌症疼痛鞘内药物输注系统植入后感染并发症发生率低,尽管常合并抗癌治疗或白细胞减少
79.3%的患者在围术期接受了至少一种抗癌治疗,25.8%存在白细胞减少,但手术部位感染率仅为0.9%(95%CI 0.1%-3.3%)。结论认为,尽管常合并抗癌治疗和白细胞减少,IDDS植入后感染风险仍低,抗癌治疗不应成为实施IDD的障碍。
要点
- 癌症疼痛患者IDDS植入后SSI发生率为0.9%(95%CI 0.1%-3.3%)。
- 79.3%患者围术期接受抗癌治疗,25.8%存在白细胞减少,但感染率仍低。
- 合并抗癌治疗或白细胞减少不应阻碍癌症疼痛的IDD治疗。
核心结论
- 癌症疼痛患者植入IDDS后手术部位感染风险低,尽管围术期常合并抗癌治疗和白细胞减少。
- 并存的抗癌治疗不应成为实施IDD治疗癌症疼痛的障碍。
研究设计与样本
- 收集人口学、健康状况、预防性抗生素、手术时长、植入前30天内白细胞减少(WBC<4.0 K/µL)或中度中性粒细胞减少(ANC<1000/μL)及围术期抗癌治疗或全身皮质类固醇使用情况,评估植入后6个月内SSI发生率。
主要发现
- 79.3%的患者在植入前或后30天内接受至少一种抗癌治疗,42.4%接受多种抗癌治疗。
- 治疗包括化疗46.5%、免疫治疗28.6%、全身类固醇32.3%、放疗28.1%。
- 25.8%的患者在植入前30天内有白细胞减少,3.2%有中度中性粒细胞减少。
- 发生2例感染并发症,感染率为0.9%(95%CI,0.1%-3.3%),发生SSI者之间共享特征有限。
临床怎么用
- 对于癌症疼痛患者,即使围术期接受抗癌治疗或存在白细胞减少,仍可考虑IDDS植入。
- 抗癌治疗不应被视为IDD实施的障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy of intrathecal drug delivery (IDD) for cancer-related pain is well established. Cancer therapies are often associated with immunosuppression and increased risk of infection, and the rate of infection after intrathecal drug delivery system (IDDS) implant in cancer patients has been reported as 2.4%-6.3%. Our objective is to report on the rate of surgical site infections (SSI) in patients implanted with IDDS for cancer-related pain and to provide a data-driven discussion on the relationship between antineoplastic treatment, leukopenia, and other clinical or demographic characteristics and SSI. METHODS: Following local institutional review board approval, we conducted a retrospective chart review of IDDS implants from May 2014 through December 2018. Data collected included demographic data, health status, prophylactic antibiotic administration, surgery duration, presence of leukopenia (white blood cell [WBC] count of <4.0 K/µL) or moderate neutropenia (absolute neutrophil count [ANC] of <1000/μL) within the 30 days before IDDS implant, and details of antineoplastic treatment or systemic corticosteroid use in the perioperative period. This information was assessed in relation to SSI incidence up to 6 months following implant. RESULTS: Two hundred seventeen IDDS implants were identified. A majority of patients (79.3%) received ≥1 form of antineoplastic therapy within 30 days before or after implant, and 42.4% received multiple forms of antineoplastic therapy. Therapies included chemotherapy in 46.5%, immunotherapy in 28.6%, systemic steroids in 32.3%, and radiation therapy in 28.1%. One-quarter of patients (25.8%) were leukopenic within 30 days before implant, with 3.2% having moderate neutropenia. There were 2 infectious complications representing an infection rate of 0.9% (95% CI, 0.1%-3.3%), with limited shared characteristics between those experiencing SSI. CONCLUSIONS: SSI risk after IDDS placement for cancer pain is low, despite frequent concurrent antineoplastic therapy and leukopenia in the perioperative period. Concomitant cancer therapies should not be a barrier to the implementation of IDD for cancer pain.
引用
- Sindt JE, Larsen SD, Dalley AP, et al. The Rate of Infectious Complications After Intrathecal Drug Delivery System Implant for Cancer-Related Pain Is Low Despite Frequent Concurrent Anticancer Treatment or Leukopenia. Anesth Analg. 2020. PMID: 31990731. doi:10.1213/ANE.0000000000004639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。